...mos (0.03-30.06 mos). Discontinuations due to NCI-CTCAE Grade 3-4 toxicities were used to assess cross intolerance betwe...
...mos vs 74% of imatinib pts. Analysis of progression-free survival at 24 mos favored dasatinib (86% vs 65%, p=0.0012); re...
...mos), 22% pts relapsed within median of 15 mos (8-42), including 2 after SCT without imatinib maintenance. In the de nov...
...mos.,To date, 29 Pts have been enrolled, 17 in chronic phase (CP), 6 in accelerated phase (AP) and 6 in myeloid blast ph...
...MOS-SSS), Zung Self-rating Depression Scale (SDS), and the European Organization for Research and Treatment of Cancer (E...
...MOs). Median age was 43 (34.5-50) and there were 83/140 (60%) females. MLPs and MOs agreed in their responses to most of...
...mos and another 7 mos after study entry. One pt withdrew consent; 1 pt died of disease within 5 days of study entry; 1 p...
...mos, range <1 mo -28.2 mos. Since 2005, 2,217 pts have received adj T. Of these, 866 pts have complete records available...
...mos]), or database end (12/31/2005). Kaplan-Meier analyses were conducted to evaluate survival time. Disease progression...
...MOs) to share important medical advances. Hence, we surveyed Canadian MOs to determine their use of the internet, assess...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
